Detalhe da pesquisa
1.
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer.
Br J Cancer
; 130(6): 941-950, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38245661
2.
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors.
Br J Cancer
; 128(12): 2227-2235, 2023 06.
Artigo
Inglês
| MEDLINE | ID: mdl-37087488
3.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Br J Cancer
; 129(1): 38-45, 2023 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37120671
4.
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer.
Br J Cancer
; 128(1): 30-41, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36335217
5.
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10.
Br J Cancer
; 128(2): 255-265, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36482193
6.
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes.
Br J Cancer
; 128(2): 342-353, 2023 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36402875
7.
Lurbinectedin in patients with pretreated endometrial cancer: results from a phase 2 basket clinical trial and exploratory translational study.
Invest New Drugs
; 41(5): 677-687, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37556023
8.
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review.
Future Oncol
; 19(9): 663-678, 2023 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37128990
9.
A plain language summary of results from the GARNET study of dostarlimab in patients with endometrial cancer.
Future Oncol
; 19(25): 1709-1714, 2023 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-37381977
10.
Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study.
Int J Gynecol Cancer
; 33(8): 1253-1259, 2023 08 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37072323
11.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 23(4): 465-478, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-35298906
12.
Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.
Clin Exp Immunol
; 209(1): 4-21, 2022 07 22.
Artigo
Inglês
| MEDLINE | ID: mdl-35020853
13.
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
Int J Gynecol Cancer
; 2022 Aug 16.
Artigo
Inglês
| MEDLINE | ID: mdl-35973737
14.
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Lancet Oncol
; 22(7): 1034-1046, 2021 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34143970
15.
Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin.
Cancer Invest
; 39(6-7): 466-472, 2021.
Artigo
Inglês
| MEDLINE | ID: mdl-34075851
16.
Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: A multicenter, randomized, controlled, open-label phase 3 study (CORAIL).
Gynecol Oncol
; 163(2): 237-245, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34521554
17.
Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Gynecol Oncol
; 163(3): 490-497, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34602290
18.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artigo
Inglês
| MEDLINE | ID: mdl-33752918
19.
Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Int J Gynecol Cancer
; 31(11): 1428-1436, 2021 11.
Artigo
Inglês
| MEDLINE | ID: mdl-34610971
20.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Int J Gynecol Cancer
; 31(12): 1589-1594, 2021 12.
Artigo
Inglês
| MEDLINE | ID: mdl-34593565